Section Arrow
Quote
PLUR.NASDAQ
- Pluri
Quotes are at least 15-min delayed:2025/12/18 11:22 EST
Regular Hours
Last
 3.2
+0.235 (+7.93%)
Day High 
3.2 
Prev. Close
2.965 
1-M High
4.1199 
Volume 
41.73K 
Bid
3.19
Ask
3.3
Day Low
2.915 
Open
2.99 
1-M Low
2.82 
Market Cap 
27.44M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.18 
20-SMA 3.41 
50-SMA 3.75 
52-W High 7.13 
52-W Low 2.82 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.13/-1.90
Enterprise Value
33.54M
Balance Sheet
Book Value Per Share
-1.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.34M
Operating Revenue Per Share
0.03
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ATHAAthira Pharma Inc.7.28+3.145+76.06%-- 
RXRXRecursion Pharmaceuticals4.65-0.03-0.64%-- 
PYXSPyxis Oncology1.8-1.57-46.59%-- 
INSMInsmed Incorporated166.7051-31.7549-16.00%-- 
VTGNVistagen Therapeutics, Inc.0.8022-0.0588-6.83%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.